 So transcription factors, if one looks at the structure of their shape, one finds that they lack deep, greasy crevices on their surface. This is important because to design a drug to hit a protein requires having a pocket with which to fit the drug into. And so transcription factors unfortunately lack those classical druggable properties needed to develop medicines in a simple fashion. My lab recently has identified a new strategy for controlling a transcription factor that promotes acute myeloid leukemia. This transcription factor is called MF2C, and despite this well-appreciated role in leukemia, to date no one has identified a way to target this protein with drugs. Using a technology involving the use of CRISPR genome editing, we have discovered a approach to control this MF2C protein. This leads to a potential new therapeutic opportunity for drug discovery, which we are intensely pursuing. But more broadly, these efforts are leading us to try to apply this to many other types of cancer in which transcription factors lie at the root cause.